Abbott's Minimally Invasive MitraClip® System for Mitral Regurgitation Demonstrates Positive Clinical and Quality-of-Life Results for Patients Too High Risk for Surgery (via PR Newswire)SAN FRANCISCO, March 10, 2013 /PRNewswire/ — Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company’s first-in-class catheter-based MitraClip® System for the treatment of mitral regurgitation (MR). …
published: March 11, 2013 in: Abbott, Cardio, Clinical Studies/Trials, Congresses and Meetings